Glycopyrrolate oral - Shionogi

Drug Profile

Glycopyrrolate oral - Shionogi

Alternative Names: Cuvposa; FHPC 02; Glycopyrrone bromide; Glycopyrronium bromide; Oral glycopyrrolate liquid

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Developer Pediapharm; Shionogi Pharma
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sialorrhoea
  • New Molecular Entity No

Highest Development Phases

  • Marketed Sialorrhoea

Most Recent Events

  • 28 Jun 2017 Pediapharm expects to get approval for Sialorrhoea in Canada before October 2017 and launch the product by the end of December 2017
  • 03 Aug 2016 Preregistration for Sialorrhoea in Canada (PO)
  • 25 Feb 2016 Pediapharm announces intention to submit application for regulatory approval to Health Canada in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top